Application of Plackett–Burman Screening Design for Formulation of Telmisartan Nanosuspension

Developing formulations for medications with low water solubility and low oral bioavailabilitypresents significant challenges. Poor water solubility and a slow rate of dissolution are issuesfor the majority of newly developed and well-established biologically active compounds.Telmisartan (TM) is a BCS class-II medication characterized by low solubility as well as highpermeability. The current study set out to determine crucial formulation and processingcharacteristics that could affect the nanosuspension's quality. Using the nanoprecipitationultrasonication process, a poorly soluble medication was converted into a nanosuspension formulation. In order to screen five independent factors—the amount of stabilizer (mg) (X2), the amount of Telmisartan (mg) (X1), the volume ratio of solvent to anti-solvent (X3), the speed of stirring (RPM) (X4), and the sonication time (min) (X5)—a total of eight experiments werecreated. The dependent factors used were saturation solubility (μg/ml) and mean particle size(nm). The acquired results demonstrated that, in comparison to all other stabilizers, the nanosuspension made with Poloxamer 407 has improved saturation solubility. The amount oftelmisartan and the speed at which the mixture is stirred were also discovered to be potentialformulation and processing parameters that exert considerable influence on the quality of thetelmisartan nanosuspension.